Teva Outperforms Quarterly Estimates but Lowers 2026 Forecast Due to Projected Revlimid Sales Erosion
Teva reported strong quarterly results but lowered its 2026 guidance due to generic Revlimid competition. The drugmaker expects a revenue decline of over $1 billion.
Insights:
Teva Pharmaceutical Industries Ltd. reported stronger-than-expected results for the October–December quarter on Wednesday. The company earned $0.96 per diluted share excluding one-time items, which marked a significant increase from the $0.71 recorded a year earlier. Quarterly revenue reached $4.71 billion, representing an 11% rise in dollar terms. These figures outperformed analyst forecasts compiled by LSEG I/B/E/S, which had estimated earnings of $0.64 per share and revenue of $4.32 billion.
